EMA PRAC, SK Biospharma's Epilepsy Treatment Ontozry Mandates Liver Function Monitoring Due to Risk of Liver Injury
EMA PRAC's Safety Warning and Measures
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has mandated new monitoring requirements for SK Biospharma's epilepsy treatment Ontozry (active ingredient cenobamate) following reports of severe liver injury cases. The committee has recommended that liver function tests (LFT) be conducted before initiating treatment and periodically during the course of therapy. This is due to the increased risk of drug-induced liver injury (DILI) in epilepsy patients, who often receive multiple medications. The regulatory authority's decision to issue a Direct Healthcare Professional Communication (DHPC) reflects the necessity of prompt risk management to maintain clinical trust.
Ontozry's Dual Mechanism and Market Position
Ontozry, with its unique dual mechanism of voltage-gated sodium channel blockade and GABA-A receptor allosteric modulation, has demonstrated strong seizure control in patients with refractory partial seizures. It has rapidly expanded its global market share, outperforming existing standard treatments such as UCB's Vimpat (active ingredient lacosamide). This safety warning comes at a time when Ontozry is gaining dominance in the $10 billion global epilepsy market, potentially slowing its short-term prescription growth. However, the establishment of a thorough monitoring system could serve as a positive catalyst for long-term prescription safety.
Partnership Structure and Financial Impact Assessment
Angelini Pharma, the European commercialization partner, inherited the licensing agreement with SK Biospharma after acquiring Arvelle Therapeutics for up to $960 million in 2021. Under the contract terms, SK Biospharma receives milestones and royalties based on European sales, meaning the new monitoring requirements could impact Angelini Pharma's performance and SK Biospharma's financial inflows. Given that the U.S. brand name Xcopri's growth is critical to SK Biospharma's goal of achieving KRW 706.7 billion in revenue by 2025, investors should monitor the potential spillover of European safety concerns into U.S. prescribing behavior. Investors should track quarterly sales trends and any delays in milestone payments.
Regulatory Approval History and Response Strategy Outlook
Ontozry received U.S. FDA approval in November 2019 and final marketing authorization from the European EMA in March 2021, establishing itself as a global blockbuster. The detection of this safety signal is interpreted as a routine risk mitigation measure by regulatory authorities to manage adverse reactions identified during post-marketing surveillance. The company must swiftly distribute mandatory LFT guidelines to healthcare professionals and educate on dosage adjustment protocols to prevent rebound seizures due to abrupt discontinuation. The effectiveness of these proactive measures will determine whether further regulatory actions, such as stricter prescription restrictions, are avoided.
The EMA PRAC's mandatory liver injury (DILI) monitoring requirement is likely to act as a short-term prescribing hurdle for Ontozry (active ingredient cenobamate) in the $10 billion global epilepsy treatment market, particularly in comparison to competing drugs such as UCB's Vimpat. However, as Ontozry is already a marketed drug with FDA and EMA approvals, the provision of thorough liver function test (LFT) guidelines can enhance long-term prescription safety and trust, mitigating adverse event risks. From a research perspective, elucidating the off-target toxicity pathways of the drug's differentiated dual mechanism (NaV/GABA-A) has emerged as a new challenge, and enhanced safety evaluation standards are expected to apply to future competitive pipeline developers. In the medium to long term, the stability of Angelini Pharma's European distribution and the receipt of up to $960 million in milestone payments will be key variables determining the speed of SK Biospharma's valuation re-rating.